

Nicoletta Testoni

List of Publications by Citations

Source: <https://exaly.com/author-pdf/854304/nicoletta-testoni-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

163
papers

4,666
citations

37
h-index

66
g-index

163
ext. papers

5,109
ext. citations

3.3
avg, IF

3.96
L-index

#	Paper	IF	Citations
163	ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1166-1173	2.2	308
162	Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. <i>Blood</i> , 2005 , 106, 35-9	2.2	288
161	Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. <i>Blood</i> , 2001 , 98, 3074-81	2.2	275
160	The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. <i>Haematologica</i> , 2007 , 92, 1173-9	6.6	177
159	Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. <i>Blood</i> , 2009 , 114, 4933-8	2.2	176
158	Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. <i>Blood</i> , 2009 , 113, 4497-504	3.4	158
157	Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. <i>Haematologica</i> , 2007 , 92, 401-4	6.6	150
156	A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. <i>Blood</i> , 2002 , 99, 1527-35	2.2	147
155	AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. <i>Blood</i> , 2009 , 114, 3024-32	2.2	139
154	Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. <i>Journal of Clinical Oncology</i> , 2000 , 18, 2273-81	2.2	133
153	Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. <i>Blood</i> , 2002 , 99, 443-9	2.2	121
152	First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. <i>Haematologica</i> , 2004 , 89, 826-31	6.6	121
151	Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. <i>Blood</i> , 2003 , 102, 1588-94	2.2	100
150	Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 16811-6	11.5	88
149	Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. <i>Blood</i> , 2012 , 120, 761-7	2.2	85
148	Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. <i>Blood</i> , 2004 , 104, 4245-51	2.2	85
147	Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. <i>Blood</i> , 2011 , 117, 5591-9	2.2	78

146	Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. <i>Clinical Cancer Research</i> , 2006 , 12, 3037-42	12.9	78
145	Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. <i>Haematologica</i> , 2008 , 93, 1792-6	6.6	74
144	Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. <i>British Journal of Haematology</i> , 2003 , 120, 251-6	4.5	72
143	Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. <i>Blood</i> , 2011 , 117, 6793-800	3.3	66
142	Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. <i>Blood</i> , 2004 , 103, 2284-90	2.2	60
141	Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34 ⁻ cell population with intrinsic resistance to imatinib. <i>Blood</i> , 2009 , 114, 5191-200	2.2	58
140	Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. <i>American Journal of Hematology</i> , 2009 , 84, 215-20	7.1	56
139	The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. <i>Haematologica</i> , 2009 , 94, 205-12	6.6	54
138	Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. <i>Blood</i> , 2009 , 114, 4939-43	2.2	54
137	Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. <i>Blood</i> , 2009 , 113, 3428-34	2.2	53
136	Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. <i>Journal of Clinical Oncology</i> , 2006 , 24, e51-2	2.2	52
135	Chromothripsis in acute myeloid leukemia: biological features and impact on survival. <i>Leukemia</i> , 2018 , 32, 1609-1620	10.7	50
134	Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome. <i>Haematologica</i> , 2008 , 93, 770-4	6.6	49
133	NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia. <i>Haematologica</i> , 2007 , 92, 1268-9	6.6	49
132	Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. <i>Haematologica</i> , 2007 , 92, 101-5	6.6	49
131	Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2748-54	2.2	48
130	Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. <i>Journal of Clinical Oncology</i> , 2008 , 26, 106-11	2.2	40
129	The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. <i>Haematologica</i> , 2010 , 95, 1415-9	6.6	39

128	Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. <i>British Journal of Haematology</i> , 2005 , 131, 172-9	4.5	39
127	Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up. <i>American Journal of Hematology</i> , 2015 , 90, 515-23	7.1	38
126	Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. <i>Blood</i> , 2013 , 121, 5138-44	2.2	36
125	Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage. <i>Experimental Hematology</i> , 2002 , 30, 126-34	3.1	35
124	Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. <i>Journal of Clinical Oncology</i> , 2006 , 24, 454-9	2.2	34
123	B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. <i>Leukemia Research</i> , 2010 , 34, e282-5	2.7	33
122	Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival. <i>Stem Cell Research and Therapy</i> , 2018 , 9, 271	8.3	32
121	Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response. <i>Clinical Cancer Research</i> , 2009 , 15, 1059-63	12.9	27
120	Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. <i>Experimental Hematology</i> , 2005 , 33, 1521-30	3.1	27
119	Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. <i>Journal of Clinical Oncology</i> , 2006 , 24, e4-5	2.2	26
118	Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2000 , 109, 722-8	4.5	25
117	Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 99	22.4	24
116	Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. <i>Cancer Genetics and Cytogenetics</i> , 2010 , 199, 76-80		24
115	The presence of lymphoid-associated antigens in adult acute myeloid leukemia is devoid of prognostic relevance. <i>Stem Cells</i> , 1995 , 13, 428-34	5.8	24
114	Cytogenetic analyses in 89 patients with secondary hematologic disorders--results of a cooperative study. <i>Cancer Genetics and Cytogenetics</i> , 1987 , 26, 65-74		23
113	Chromosome studies in patients with Philadelphia chromosome-positive chronic myeloid leukemia submitted to bone marrow transplantation--results of a European Cooperative Study. <i>Cancer Genetics and Cytogenetics</i> , 1987 , 26, 5-13		21
112	All-trans retinoic acid significantly reduces the incidence of early hemorrhagic death during induction therapy of acute promyelocytic leukemia. <i>European Journal of Haematology</i> , 2000 , 64, 139-44	3.8	20
111	Philadelphia-positive acute myelomonocytic leukemia with inversion of chromosome 16 and eosinobasophils. <i>American Journal of Hematology</i> , 1988 , 27, 69-71	7.1	20

110	Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation. <i>Leukemia and Lymphoma</i> , 2006 , 47, 469-72	1.9	19
109	Inv(16) acute myeloid leukemia cells show an increased sensitivity to cytosine arabinoside in vitro. <i>European Journal of Haematology</i> , 1998 , 60, 161-5	3.8	18
108	The type of BCR/ABL junction does not predict the survival of patients with Ph1-positive chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 1993 , 84, 265-8	4.5	18
107	Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. <i>British Journal of Haematology</i> , 2007 , 136, 87-95	4.5	17
106	The cytogenetic response as a surrogate marker of survival. <i>Seminars in Hematology</i> , 2003 , 40, 56-61	4	17
105	Cytogenetic and molecular studies in patients with chronic myeloid leukemia and variant Philadelphia translocations. <i>Cancer Genetics and Cytogenetics</i> , 1989 , 42, 191-201		17
104	Inversions of chromosome 12 in human malignancies. <i>Cancer Genetics and Cytogenetics</i> , 1987 , 28, 113-8		17
103	Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. <i>Haematologica</i> , 2008 , 93, 1017-24	6.6	16
102	Chromosome studies in patients with acute nonlymphocytic or acute lymphocytic leukemia submitted to bone marrow transplantation--results of a European cooperative study. <i>Cancer Genetics and Cytogenetics</i> , 1987 , 26, 51-8		16
101	High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party. <i>Blood</i> , 2008 , 112, 181-181	2.2	16
100	Characterization of 12p molecular events outside ETV6 in complex karyotypes of acute myeloid malignancies. <i>British Journal of Haematology</i> , 1999 , 107, 340-6	4.5	15
99	Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients. <i>Oncotarget</i> , 2015 , 6, 31284-94	3.3	15
98	Four-chromosomes complex translocations in acute promyelocytic leukemia: description of two cases. <i>European Journal of Haematology</i> , 1994 , 52, 129-33	3.8	14
97	Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy. <i>Oncotarget</i> , 2017 , 8, 29906-29913	3.3	14
96	Interferon-alpha effects on stromal compartment of normal and chronic myeloid leukemia hematopoiesis. <i>Leukemia and Lymphoma</i> , 1993 , 11 Suppl 1, 113-8	1.9	13
95	Granulocytic sarcomas: clinical, diagnostic and therapeutical aspects. <i>Leukemia and Lymphoma</i> , 1997 , 24, 349-53	1.9	12
94	Vimentin and keratin intermediate filaments expression by K562 leukemic cell line. <i>Leukemia Research</i> , 1986 , 10, 29-33	2.7	12
93	Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial. <i>Blood</i> , 2010 , 116, 359-359	2.2	12

92	Conjunctival and Limbal Transplantation From the Same Living-Related Bone Marrow Donor to Patients With Severe Ocular Graft-vs-Host Disease. <i>JAMA Ophthalmology</i> , 2017 , 135, 1123-1125	3.9	11
91	BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. <i>PLoS ONE</i> , 2013 , 8, e81425	3.7	11
90	t(8;14)(q11;q32) in acute lymphoid leukemia: description of two cases. <i>Cancer Genetics and Cytogenetics</i> , 1993 , 67, 55-8		11
89	Acute nonlymphocytic leukemias and dysmyelopoietic syndromes in patients treated for Hodgkin's lymphoma. <i>Cancer Genetics and Cytogenetics</i> , 1983 , 9, 217-26		11
88	Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia. <i>Cancers</i> , 2019 , 11,	6.6	11
87	Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2058-64	1.9	9
86	Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014 , 14, e101-4	2	9
85	Treatment of Ph+ chronic myeloid leukemia by gamma interferon. <i>Blut</i> , 1989 , 59, 15-20		8
84	Chromosome 12 rearrangement with breakage at the p11 level in hematologic disorders: report of four cases. <i>Cancer Genetics and Cytogenetics</i> , 1985 , 15, 309-14		8
83	Up-Front Thalidomide-Dexamethasone (THAL) and Double Autologous Transplantation (Double TX) for Multiple Myeloma: Comparison with Double TX without Added Thalidomide and Prognostic Implications of Chromosome 13 Deletion and Translocation t(4;14).. <i>Blood</i> , 2006 , 108, 3081-3081	2.2	8
82	Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line. <i>Blood</i> , 2008 , 112, 185-185	2.2	8
81	Rescue of genomic information in adult acute lymphoblastic leukaemia (ALL) with normal/failed cytogenetics: a GIMEMA centralized biological study. <i>British Journal of Haematology</i> , 2010 , 149, 70-8	4.5	7
80	Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy. <i>Leukemia Research</i> , 2009 , 33, e218-20	2.7	7
79	FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia. <i>Leukemia and Lymphoma</i> , 1996 , 22, 173-6	1.9	7
78	Structural organization of BCR-ABL gene in chronic phase and blast transformation in chronic myeloid leukemia patients. <i>Leukemia and Lymphoma</i> , 1993 , 11 Suppl 1, 51-6	1.9	7
77	Epigenetically induced ectopic expression of UNCX impairs the proliferation and differentiation of myeloid cells. <i>Haematologica</i> , 2017 , 102, 1204-1214	6.6	6
76	Recurrent Gastrointestinal Hemorrhage in Treatment with Dasatinib in a Patient Showing SMAD4 Mutation with Acute Lymphoblastic Leukemia Philadelphia Positive and Juvenile Polyposis Hereditary Hemorrhagic Telangiectasia Syndrome. <i>Hematology Reports</i> , 2013 , 5, 26-7	0.9	6
75	Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. <i>Leukemia and Lymphoma</i> , 2009 , 50, 114-8	1.9	6

74	FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities. <i>BMC Cancer</i> , 2014 , 14, 396	4.8	5
73	4q12 translocations with GSX2 expression identify a CD7(+) acute myeloid leukaemia subset. <i>British Journal of Haematology</i> , 2015 , 171, 141-5	4.5	5
72	Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib. <i>Leukemia Research</i> , 2011 , 35, 1527-9	2.7	5
71	FISH analysis reveals frequent co-occurrence of 4q24/TET2 and 5q and/or 7q deletions. <i>Leukemia Research</i> , 2012 , 36, 37-41	2.7	4
70	A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. <i>Leukemia and Lymphoma</i> , 2011 , 52, 2329-35	1.9	4
69	Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration. <i>Leukemia Research</i> , 2010 , 34, e246-7	2.7	4
68	Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. <i>European Journal of Haematology</i> , 2008 , 80, 31-6	3.8	4
67	Does the type of BCR/ABL junction predict the survival of patients with Ph1-positive chronic myeloid leukemia?. <i>Leukemia and Lymphoma</i> , 1995 , 16, 231-6	1.9	4
66	Cytogenetic events after bone marrow transplantation for Philadelphia chromosome positive chronic myeloid leukemia. <i>Leukemia Research</i> , 1991 , 15, 289-96	2.7	4
65	Mutations at Residues 315 and 317 in the ABL Kinase Domain Are the Main Cause of Resistance to Dasatinib in Philadelphia-Positive (Ph+) Leukemia Patients (pts).. <i>Blood</i> , 2006 , 108, 836-836	2.2	4
64	Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party.. <i>Blood</i> , 2009 , 114, 2205-2205	2.2	4
63	Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse.. <i>Blood</i> , 2012 , 120, 2601-2601	2.2	4
62	Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 2479-2486	4	3
61	Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities. <i>Genes Chromosomes and Cancer</i> , 2016 , 55, 375-88	5	3
60	Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation. <i>Annals of Hematology</i> , 2013 , 92, 1271-80	3	3
59	Chromothripsis in acute myeloid leukemia: biological features and impact on survival. <i>Leukemia</i> , 2017 ,	10.7	3
58	In Vitro Activity of Alpha-Interferon on Granulocyte-Macrophage Precursors in Chronic Myeloid Leukemia (CML): Correlation with Clinical Responsiveness. <i>Leukemia and Lymphoma</i> , 1992 , 6, 155-160	1.9	3
57	Gene Expression Profile (GEP) of Chronic Myeloid Leukemia (CML) Patients at Diagnosis: Two Distinguished Subgroups of CML Patients Identified, Based on a Molecular Signature, Irrespective of Their Sokal Risk Score. <i>Blood</i> , 2008 , 112, 3190-3190	2.2	3

56	The GNAS1 gene in myelodysplastic syndromes (MDS). <i>Leukemia Research</i> , 2014 , 38, 804-7	2.7	2
55	Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement: clinical implications. <i>Leukemia Research</i> , 2008 , 32, 1941-3	2.7	2
54	Quantitative evaluation of BCR-ABL amount of transcript post mobilization with G-CSF of peripheral blood stem cells from chronic myeloid leukemia patients in cytogenetic response. <i>Leukemia and Lymphoma</i> , 2000 , 39, 113-20	1.9	2
53	Molecular and cytogenetic studies of a patient with Philadelphia-negative, BCR-positive chronic myeloid leukemia and t(12;12)(q13;p12). <i>Genes Chromosomes and Cancer</i> , 1990 , 1, 284-8	5	2
52	Cytogenetic and molecular analyses in Philadelphia chromosome positive acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 1988 , 69, 424-6	4.5	2
51	Imatinib Mesylate Can Induce Molecular Complete Remission in Idiopathic Hypereosinophilic Syndrome (HES). A Phase II Multicentric Italian Clinical Trial.. <i>Blood</i> , 2005 , 106, 375-375	2.2	2
50	A Prospective Study of Imatinib 400 mg vs 800 mg Frontline in High Risk Ph+ Chronic Myeloid Leukemia (CML) Patients.. <i>Blood</i> , 2007 , 110, 26-26	2.2	2
49	The cytogenetic response as a surrogate marker of survival. <i>Seminars in Hematology</i> , 2003 , 40, 56-61	4	2
48	FGFR1 and KAT6A rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features. <i>American Journal of Hematology</i> , 2016 , 91, E14-6	7.1	2
47	MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2020 , 105, 47-55	3.8	1
46	Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia. <i>Hematology</i> , 2008 , 13, 1-12	2.2	1
45	European Multicenter Experience on Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFRα Rearrangement treated with Imatinib.. <i>Blood</i> , 2004 , 104, 1507-1507	2.2	1
44	Fludarabine Based Regimen (FLAI) Is an Effective Treatment for Induction of Multidrug Resistant Pgp-Positive Acute Myeloid Leukemia Patients.. <i>Blood</i> , 2005 , 106, 1857-1857	2.2	1
43	High-Resolution Molecular Allelokaryotyping of Chronic Myeloid Leukemia Patients in Blast Crisis by 6.0 SNP-Arrays Shows a High-Frequency of Uniparental Disomy and Focal Copy Number Alterations Affecting the Whole Sequence or Specific Exons of Oncogenes and Tumor Suppressor Genes. <i>Blood</i> , 2009 , 114, 2174-2174	2.2	1
42	Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.. <i>Blood</i> , 2009 , 114, 860-860	2.2	1
41	Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party. <i>Blood</i> , 2011 , 118, 453-453	2.2	1
40	Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis. <i>Blood</i> , 2013 , 122, 2622-2622	2.2	1
39	Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7038-7038	2.2	1

38	Superiority of First-Line Thalidomide-Dexamethasone over Vincristine-Doxorubicin-Dexamethasone in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.. <i>Blood</i> , 2004 , 104, 1489-1489	2.2	1
37	Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen. <i>Blood</i> , 2010 , 116, 4335-4335	2.2	1
36	Pediatric Therapy In Adult Acute Lymphoblastic Leukemia: Updated Experience of a Single Centre. <i>Blood</i> , 2010 , 116, 4338-4338	2.2	1
35	A novel t(2;10)(q31;p12) balanced translocation in acute myeloid leukemia. <i>Hematology Reports</i> , 2012 , 4, e27	0.9	0
34	Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2004 , 151, 85-6		0
33	Fingerprinting Of HLA-DQA by polymerase chain reaction and heteroduplex analysis. <i>Molecular and Cellular Probes</i> , 1996 , 10, 123-7	3.3	0
32	BCR-ABL Fusion Transcript Do Not Significantly Influence the Outcome of Chronic Myeloid Leukemia Patients In Early Chronic Phase Treated with Imatinib Mesylate: a GIMEMA CML WP Analysis.. <i>Blood</i> , 2010 , 116, 1230-1230	2.2	0
31	Single or Double Autologous Stem Cell Transplantation Before and After the Era of Novel Agents. <i>Clinical Lymphoma and Myeloma</i> , 2009 , 9, S51-S52		
30	Venetoclax Plus Hypomethylating Agents for Relapsed/Refractory Acute Myeloid Leukemia (AML) Is Safe and Manageable in the Outpatient Setting. <i>Blood</i> , 2020 , 136, 14-15	2.2	
29	Imatinib Therapy for Chronic Myeloid Leukemia Patients Who Relapse after Allogeneic Stem Cell Transplantation: A Molecular Analysis.. <i>Blood</i> , 2004 , 104, 4655-4655	2.2	
28	Imatinib in the Treatment of CML Patients \geq 5 Years Old in Late Chronic Phase: Results of a Phase II Study of the GIMEMA CML Working Party.. <i>Blood</i> , 2004 , 104, 2935-2935	2.2	
27	Heterogeneous Chromosomal Mechanisms Generating the 5'RUNX1/3'CBFA2T1 Gene in Acute Myeloid Leukemia.. <i>Blood</i> , 2004 , 104, 4272-4272	2.2	
26	Prediction of Response to Imatinib by Prospective Quantitation of BCR-ABL Transcript in Late Chronic Phase Chronic Myeloid Leukemia Patients By GIMEMA Working Party on CML.. <i>Blood</i> , 2004 , 104, 4672-4672	2.2	
25	Interleukin-12 Gene Expression into Acute Myeloid Leukemia-Derived Dendritic Cells Overcomes T-Cell Functional Impairment Induced by Leukemic Microenvironment.. <i>Blood</i> , 2004 , 104, 1816-1816	2.2	
24	Superior Complete Remission/Very Good Partial Remission Rate with Peri-Transplant Administration of Thalidomide-Dexamethasone for Newly Diagnosed Multiple Myeloma.. <i>Blood</i> , 2005 , 106, 5474-5474	2.2	
23	Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia (CML) on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML).. <i>Blood</i> , 2005 , 106, 1100-1100	2.2	
22	Imatinib 800 mg: Preliminary Results of a Phase II Trial of the GIMEMA CML Working Party in Intermediate Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients. <i>Blood</i> , 2005 , 106, 1098-1098	2.2	
21	Comparison of Cytogenetics and Interphase Fluorescence In Situ Hybridization in Newly Diagnosed Ph+ Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate. A Study by the GIMEMA Working Party on CML. On Behalf of GWP on CML.. <i>Blood</i> , 2005 , 106, 4857-4857	2.2	

20	Chromosome 9 and 22 Breakpoints Cluster Regions Definition of Deleted Sequences on der(9) in Chronic Myeloid Leukemia.. <i>Blood</i> , 2005 , 106, 4842-4842	2.2
19	FLT-3 Activity and Its Response to Drugs Can Be Determined in AML Blast Cells by FLT-3 Phosphorylation Status Using Flow Cytometry.. <i>Blood</i> , 2006 , 108, 2308-2308	2.2
18	NPM Mutations and Not FLT3 Mutations Are a Potential Marker for Monitoring Minimal Residual Disease in Acute Myeloid Leukemia.. <i>Blood</i> , 2006 , 108, 2016-2016	2.2
17	Impact of Age in the Outcome of Patients with Chronic Myeloid Leukemia in Late Chronic Phase: Clinical and Molecular Results of a Phase II Study of the GIMEMA CML Working Party.. <i>Blood</i> , 2006 , 108, 4805-4805	2.2
16	Prevalence and Prognostic Significance of FLT3 Mutations in Acute Myeloid Leukemia: Association of ITDs with Poor Outcome in Patients with Normal Cytogenetics.. <i>Blood</i> , 2006 , 108, 2017-2017	2.2
15	A New Gene Expression Profile Signature CRLF2 Overexpression Based Identifies Novel Adult "Triple Negative" Acute Lymphoblastic Leukemia Subgroups. <i>Blood</i> , 2018 , 132, 5284-5284	2.2
14	A Maturation Index Defines Newly Diagnosed Multiple Myeloma Patients with Advanced Immunophenotypic and Molecular Differentiation Profiles Associated with Poor Prognosis. <i>Blood</i> , 2019 , 134, 1797-1797	2.2
13	Copy number variants signature in two patients with relapsed acute promyelocytic leukemia.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e23207-e23207	2.2
12	Microarray analysis to identify novel copy number alterations in acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11622-11622	2.2
11	Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11611-11611	2.2
10	Identification and Molecular Characterization of Two Recurrent Genomic Deletions (Type A and Type B) on 7p12 in IKZF1 Gene in a Large Cohort of BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL): on Behalf of the GIMEMA ALL Working Party. <i>Blood</i> , 2008 , 112, 428-428	2.2
9	Different Isoforms of the B-Cell Mutator Activation-Induced Cytidine Deaminase (AID) Are Aberrantly Over-Expressed in BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Patients and Promote Genetic Instability.. <i>Blood</i> , 2008 , 112, 1497-1497	2.2
8	CD34+ obtained from High Sokal Risk Chronic Myeloid Leukemia (CML) Patients (PTS) Expresses Gene Profiles (GEP) Significantly Different From CD34+ Obtained From Low Sokal Risk Patients.. <i>Blood</i> , 2009 , 114, 2174-2174	2.2
7	Evaluating the Response to Imatinib In Philadelphia-Positive Chronic Myeloid Leukemia (Ph+ CML): The Value of Major Molecular Response (MMoR) at 12 Months. <i>Blood</i> , 2010 , 116, 668-668	2.2
6	Pediatric-Like Intensified Therapy In Adult Acute Lymphoblastic Leukemia: A Single Centre Experience. <i>Blood</i> , 2011 , 118, 4261-4261	2.2
5	PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience. <i>Blood</i> , 2012 , 120, 1749-1749	2.2
4	The e13a2 BCR-ABL1 Fusion Transcript Is a Candidate Adverse Prognostic Factor In Chronic Myeloid Leukemia Patients Treated Frontline With Imatinib Mesylate. <i>Blood</i> , 2013 , 122, 1486-1486	2.2
3	4-Year Outcome Of 215 Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated Frontline With Nilotinib In Investigator-Sponsored Studies. A Report From The Gimema CML Working Party. <i>Blood</i> , 2013 , 122, 4000-4000	2.2

- 2 Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harboring T315I Mutation: The Bologna Experience. *Blood*, **2013**, 122, 3911-3911 2.2
- 1 Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4. *Blood*, **2013**, 122, 1855-1855 2.2